COMPARISON

Tesamorelin vs Vasopressin

3 attributes held for at least one of the two. 3 differ. Each value carries the register it came from and the date that register was read.

Answer

Tesamorelin is authorised or registered in 2 and Vasopressin in 7 of the 10 registers read. Tesamorelin: No trial states a phase. Vasopressin: highest phase Phase 4 (after approval). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

TesamorelinVasopressin
Registered trials
differs
24
clinicaltrials.gov · 2026-10-03
449
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: EGRIFTA SV
openfda · 2026-10-03T17:23:44.062Z
FDA-approved: VASOPRESSIN
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
differs
Application withdrawn
ema · 2026-10-03
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectTesamorelinplaceboVasopressinplacebo
Injection site erythema6.8%2.6%--
Paresthesia2.4%5.0%--
Injection site pain1.8%2.5%--
Nephrolithiasis0.8%0.5%--
Abdominal pain0.6%1.5%--

Trial register Tesamorelin: 4 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Tesamorelin side effects · Vasopressin side effects

LEGAL STATUS

Approval in each country read

CountryTesamorelinVasopressinRegister
United StatesFDA-approvedFDA-approvedRegulator FDA
European UnionApplication withdrawnNot on the registerRegulator EMA
United KingdomNot on the registerAuthorisedRegulator MHRA
CanadaAuthorisedAuthorisedRegulator Health Canada
AustraliaStatus unknownStatus unknown TGA
SwitzerlandNot on the registerAuthorisedRegulator Swissmedic
BrazilNot on the registerRegistadoRegulator ANVISA
SerbiaNot on the registerNot on the registerRegulator ALIMS
SingaporeNot on the registerRegisteredRegulator HSA
TurkeyNot on the registerRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.